Podocyte dysfunction in atypical haemolytic uraemic syndrome

被引:37
|
作者
Noris, Marina [1 ]
Mele, Caterina [1 ]
Remuzzi, Giuseppe [1 ]
机构
[1] IRCCS Ist Ric Farmacol Mario Negri, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24020 Bergamo, Italy
关键词
PROTEIN-KINASE-C; COMPLEMENT FACTOR-H; EXPERIMENTAL MEMBRANOUS NEPHROPATHY; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; THROMBOTIC MICROANGIOPATHY; SIGNAL-TRANSDUCTION; INTRACELLULAR CA2+; ENDOTHELIAL-CELLS; VEGF INHIBITION;
D O I
10.1038/nrneph.2014.250
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Genetic or autoimmune defects that lead to dysregulation of the alternative pathway of complement have been associated with the development of atypical haemolytic uraemic syndrome (aHUS), which is characterized by thrombocytopenia, haemolytic anaemia and acute kidney injury. The relationship between aHUS, podocyte dysfunction and the resultant proteinuria has not been adequately investigated. However, the report of mutations in diacylglycerol kinase epsilon (DGKE) as a cause of recessive infantile aHUS characterized by proteinuria, highlighted podocyte dysfunction as a potential complication of aHUS. DGKE deficiency was originally thought to trigger aHUS through pathogenetic mechanisms distinct from complement dysregulation; however, emerging findings suggest an interplay between DGKE and complement systems. Podocyte dysfunction with nephrodtic-range proteinuria can also occur in forms of aHUS associated with genetic or autoimmune complement dysregulation without evidence of DGKE mutations. Furthermore, proteinuric glomerulonephritides can be complicated by aHUS, possibly as a consequence of podocyte dysfunction inducing endothelial injury and prothrombotic abnormalities.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 50 条
  • [31] Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
    Keating, Gillian M.
    DRUGS, 2013, 73 (18) : 2053 - 2066
  • [32] Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)
    Wong, Edwin
    Challis, Rachel
    Sheerin, Neil
    Johnson, Sally
    Kavanagh, David
    Goodship, Timothy H. J.
    IMMUNOBIOLOGY, 2016, 221 (06) : 715 - 718
  • [33] Atypical haemolytic uraemic syndrome and mutations in complement regulator genes
    Marie-Agnès Dragon-Durey
    Véronique Frémeaux-Bacchi
    Springer Seminars in Immunopathology, 2005, 27 : 359 - 374
  • [34] A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
    Rathbone, John
    Kaltenthaler, Eva
    Richards, Anna
    Tappenden, Paul
    Bessey, Alice
    Cantrell, Anna
    BMJ OPEN, 2013, 3 (11):
  • [35] A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome
    Westra, D.
    Wetzels, J. F. M.
    Volokhina, E. B.
    van den Heuvel, L. P.
    van de Kar, N. C. A. J.
    NETHERLANDS JOURNAL OF MEDICINE, 2012, 70 (03): : 121 - 129
  • [36] Atypical haemolytic uraemic syndrome: a case of rare genetic mutation
    Sangeetha, Geminiganesan
    Jayaraj, Jaippreetha
    Ganesan, Swathi
    Puttagunta, Sreeapoorva
    BMJ CASE REPORTS, 2021, 14 (07)
  • [37] Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
    Gillian M. Keating
    Drugs, 2013, 73 : 2053 - 2066
  • [38] Factor I autoantibodies are associated with atypical haemolytic uraemic syndrome
    Kavanagh, David
    Pappworth, Isabel Y.
    Roversi, Pietro
    Tapson, John S.
    Moore, Iain
    Strain, Lisa
    Lea, Susan
    Goodship, Timothy H. J.
    Marchbank, Kevin J.
    MOLECULAR IMMUNOLOGY, 2010, 47 (13) : 2291 - 2292
  • [39] SYSTEMIC LUPUS ERYTHEMATOSUS MASQUERADING AS ATYPICAL HAEMOLYTIC URAEMIC SYNDROME
    Kuo, S.
    Graver, A.
    Kirkland, G.
    Yu, R.
    NEPHROLOGY, 2017, 22 : 64 - 64